"Personally, I do not like any of the drug profiles." I assume those are the compositions of VVUS, ARNA and OREX that are closest to potential approval.
Do you mean to include the Takeda/Amylin Pramlintide/met-leptin combination in your critique? If so, why?
Market Data 
Markets 
AI
